VALN Valneva SE
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
What changed
Recent filings, trades and moves
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.5B
- Employees
- 674
- List Date
- 2021-05-06
- CIK
- 0001836564
- Next Earnings
- 2026-11-24 (Pre-Market)
- EPS Forecast
- ($0.23)
- Homepage
- https://www.valneva.com
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which…
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -33.18% | -1.77% | -20.41% | 22.46% | 2.85% | -6.01% |
| Feb | -- | -7.60% | -13.42% | -13.62% | 25.70% | 21.20% | 2.45% |
| Mar | -- | 0.46% | -12.91% | 12.02% | -1.61% | -42.77% | -8.96% |
| Apr | -- | -26.68% | -8.59% | -2.99% | -6.14% | -14.19% | -11.72% |
| May | -8.36% | -7.02% | 18.06% | 19.80% | 0.31% | 16.82% | 6.60% |
| Jun | -9.39% | -1.94% | 18.28% | -22.80% | -11.55% | -12.10% | -6.58% |
| Jul | 3.63% | -4.29% | -1.02% | 3.38% | 28.50% | -2.36% | 4.64% |
| Aug | 82.57% | -2.98% | -4.90% | 3.83% | 22.60% | 24.26% | 20.90% |
| Sep | -37.86% | -39.94% | -16.93% | -16.92% | 41.45% | -5.86% | -12.68% |
| Oct | 48.70% | 28.11% | 0.53% | -2.08% | -19.88% | -7.63% | 7.96% |
| Nov | 32.22% | -5.19% | -1.44% | -29.57% | 3.37% | 0.85%* | 0.04% |
| Dec | -11.17% | -7.56% | -9.87% | 12.97% | -1.01% | -- | -3.33% |
| Total | 70.50% | -74.04% | -33.98% | -51.99% | 130.42% | -33.12% | 1.30% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL with confidence level 6/10
Key Drivers:
- Positive recent news headlines on regulatory progress for Lyme Shot development
- Bullish momentum indicators, such as MACD signal line crossover above zero line
- Low volatility and correlation with market indices (beta <1)
Primary Risks:
- Overbought RSI reading (>70) indicating potential sell signal
- Negative sentiment from recent headlines related to Pfizer partnership
Investment Thesis: VALN has the potential to continue its upward trend, driven by regulatory progress on Lyme Shot development. However, caution is advised due to overbought momentum and negative news sentiment.
Recent News Sentiment Impact: NEUTRAL
Technical Analysis
Trend Direction: Medium-term uptrend (1-3 months)
Support/Resistance Levels:
- SMA 50: $5.31
- Upper Bollinger Band: $6.86
Momentum Signals:
- RSI: >70 overbought (potential sell signal)
- MACD: Bullish momentum with signal line crossover above zero line
- Bollinger Bands: Overbought with price touching upper band
Volume Analysis:
- Volume SMA 20: 175709.05
- On-Balance Volume (OBV): 5714082.15
- Volume Rate of Change: 354.15%
News & Sentiment Analysis
Recent Headlines Summary: Neutral news headlines related to regulatory progress and investor alert.
Sentiment Assessment: NEUTRAL
Catalyst Identification: Regulatory approval for Lyme Shot development (medium-term catalyst)
Market Narrative: Recent negative news sentiment may have contributed to the overbought RSI reading, but overall market narrative remains positive due to regulatory progress.
Risk & Volatility Assessment
Beta Interpretation: Low volatility with beta <1 relative to SPY
Volatility Regime: Current volatility levels are low compared to historical averages
Options Market Signals:
- IV Premium vs HV30: N/A (positive = implied richer than realized)
Downside Protection: Support level at SMA 50 ($5.31) and risk management considerations.
Market Context & Positioning
Sector Performance: Relative strength in the biotechnology sector
Institutional Activity: Low institutional interest with volume patterns suggesting caution
Correlation Analysis: Low correlation with market indices (beta <1)
Relative Valuation: VALN is relatively undervalued compared to its historical average.
Key Levels & Action Items
Critical Price Levels:
- Support level at SMA 50 ($5.31)
- Resistance level at Upper Bollinger Band ($6.86)
Breakout/Breakdown Levels:
- Breakout above $6.90 for further upside
- Breakdown below $5.44 for potential bearish momentum
Time-Sensitive Catalysts: Regulatory approval for Lyme Shot development (medium-term catalyst)
Risk Management: Stop-loss levels and position sizing considerations.
Please note that this analysis is based on the provided data and may not reflect real-time market movements or future events.
VALN Options Activity & IV Rank
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
IV(call wing) − IV(ATM), in vol pointsThe same measure on the upside: how the OTM call is priced against the at-the-money strike.
- Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
- Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Loading the implied volatility surface…
Loading the implied volatility smile…
Risk Metrics
Analysis Details
Data Points: 251
Period: 252 trading days
Low volatility - stock moves less than market
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $707K | #3049 of 3716 | new | 13F | |
| Citadel Hedge fund Ken Griffin | $106K | #5780 of 6285 | new | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $3K | #4496 of 4858 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
VALN Institutional Ownership (13F)
Filings for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
VALN vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| AMGN Amgen Inc | $240.1B | 25.5 | +8.2% | +34.0% | 47 |
| GILD Gilead Sciences Inc | $209.6B | — | +6.5% | +37.2% | 64 |
| MRNA Moderna, Inc. Common Stock | $79.6B | — | +13.1% | +547.8% | 37 |
| ARGX argenx SE American Depositary Shares | $59.2B | — | — | +12.0% | 93 |
| BIIB Biogen Inc. Common Stock | $37.2B | 105.2 | +2.3% | +38.5% | 100 |
| RVMD Revolution Medicines, Inc. Common Stock | $34.6B | — | — | +102.1% | 68 |
| BNTX BioNTech SE American Depositary Share | $20.6B | — | — | −16.1% | 32 |
| EXEL Exelixis Inc | $16.7B | 19.7 | +9.1% | +51.0% | 36 |
| VALN Valneva SE American Depositary Shares | $508M | — | — | −40.1% | — |
| Peer median | $48.2B | 25.5 | +8.2% | +37.8% | 56 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.